Kendall Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.19M Sell
8,567
-85
-1% -$11.9K 0.24% 107
2025
Q4
$1.06M Sell
8,652
-260
-3% -$31.6K 0.22% 111
2025
Q3
$989K Buy
8,912
+90
+1% +$10.2K 0.22% 110
2025
Q2
$978K Buy
8,822
+105
+1% +$11.2K 0.26% 99
2025
Q1
$977K Buy
8,717
+25
+0.3% +$2.58K 0.29% 94
2024
Q4
$803K Buy
8,692
+310
+4% +$27.9K 0.23% 112
2024
Q3
$703K Buy
8,382
+1,065
+15% +$81.3K 0.22% 124
2024
Q2
$502K Buy
7,317
+3,705
+103% +$247K 0.17% 141
2024
Q1
$265K Buy
3,612
+25
+0.7% +$1.92K 0.09% 187
2023
Q4
$291K Hold
3,587
0.11% 171
2023
Q3
$269K Buy
3,587
+895
+33% +$68.8K 0.12% 167
2023
Q2
$207K Buy
+2,692
New +$215K 0.09% 190
2021
Q2
Sell
-3,125
Closed -$202K 153
2021
Q1
$202K Sell
3,125
-425
-12% -$27.4K 0.13% 139
2020
Q4
$207K Sell
3,550
-175
-5% -$10.6K 0.15% 122
2020
Q3
$235K Sell
3,725
-175
-4% -$12.1K 0.2% 108
2020
Q2
$300K Sell
3,900
-15
-0.4% -$1.15K 0.29% 93
2020
Q1
$293K Hold
3,915
0.33% 82
2019
Q4
$254K Sell
3,915
-198
-5% -$12.9K 0.2% 106
2019
Q3
$261K Hold
4,113
0.23% 98
2019
Q2
$278K Sell
4,113
-52
-1% -$3.42K 0.25% 96
2019
Q1
$271K Sell
4,165
-480
-10% -$31.9K 0.26% 94
2018
Q4
$291K Sell
4,645
-1,701
-27% -$119K 0.3% 85
2018
Q3
$490K Sell
6,346
-2,144
-25% -$162K 0.42% 71
2018
Q2
$601K Sell
8,490
-3,127
-27% -$221K 0.53% 61
2018
Q1
$876K Sell
11,617
-2,075
-15% -$165K 0.76% 43
2017
Q4
$981K Buy
+13,692
New +$1.04M 0.87% 39

Other funds holding GILD

Kendall Capital Management's GILD Position: Q1 2026 in Review

Kendall Capital Management reduced its Gilead Sciences (GILD) stake by 0.98% in Q1 2026, selling an estimated $11.9K and leaving 8,567 shares worth $1.19M. The position accounts for 0.24% of the portfolio, ranked #107.

Kendall Capital Management first reported a position in GILD in Q4 2017 and has held it in 26 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Kendall Capital Management held 8,567 shares of Gilead Sciences worth $1.19M as of Q1 2026.
  • Kendall Capital Management sold 85 Gilead Sciences shares in Q1 2026, an estimated $11.9K.
  • Gilead Sciences made up 0.24% of Kendall Capital Management's portfolio in Q1 2026, its #107 holding.
  • Kendall Capital Management first reported a position in Gilead Sciences in Q4 2017 and has held it in 26 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.